Article
CircRUNX1 Drives Immune Evasion and anti-PD1 Immunotherapy Resistance in Lung Adenocarcinoma by the miR-4739/PCSK9/MHC I Axis
2021-08-31
Abstract excerpt
<h4>Background: </h4> Lung adenocarcinoma (LUAD) is the commonest pathological subtype of lung-derived malignant tumor. Blocking the immune checkpoints interaction between programmed death-1 (PD-1) and programmed death ligand 1 (PD-L1) via naturalizing PD-1 or PD-L1 monoclonal antibody is proved to be a effective therapeutic method for drive gene negative LUAD. Dysregulation of circular RNA (circRNA) is a hallmark...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- e95ba85b-5c83-5569-9242-5d84bac76853
- DOI
- 10.21203/rs.3.rs-835938/v1
